1 |
Sorafenib Mitotane, etoposide, doxorubicin, and cisplatin PD-1 inhibitor (nivolumab) and radiotherapy ACAT inhibitor Wee-1 inhibitor Cabozantinib PD-1 inhibitor (PEM) and LAG-3 inhibitor Gemcitabine and capecitabine LEN (single-agent)
| 2 months 6 months
4 months
3 months 4 months 2 months 4 months
4 months 12 months | 56 months |
2 |
Mitotane PD-1 inhibitor (nivolumab) CSF-1R inhibitor and PD-1 inhibitor (PEM) Etoposide, doxorubicin, and cisplatin
| 7 months 5 months 2 months
2 months | 66 months |
3 |
Mitotane Etoposide, doxorubicin, and cisplatin Ipilimumab and PD-1 inhibitor (nivolumab) LEN (single-agent)
| 36 months 1 month
2 months
6 months | 68 months |
4 |
Mitotane and adjuvant radiotherapy Mitotane, etoposide, doxorubicin, and cisplatin PD-1 inhibitor (PEM) Carboplatin, etoposide, and mitotane Cabozantinib
| 18 months
13 months
6 months 13 months
6 months | 86 months |
5 |
Mitotane, etoposide, doxorubicin, and cisplatin Mitotane (single-agent) PI3K inhibitor and PD-1 inhibitor (nivolumab) Cabozantinib
| 7 months
5 months 4 months
2 months | 29 months |
6 |
Etoposide, doxorubicin, and cisplatin Etoposide Gemcitabine and docetaxel Cyclophosphamide, vincristine, and dacarbazine PD-1 inhibitor (PEM)
| 6 months
3 months 1 month 2 months
1 month | 24 months |
7 |
Etoposide, doxorubicin, and cisplatin Gemcitabine and docetaxel
| 1 month
1 month | 5 months |
8 |
Mitotane and adjuvant radiotherapy Mitotane, etoposide, doxorubicin, and cisplatin Gemcitabine and docetaxel LEN (single-agent)
| 4 months
1 month
3 months 1 month | 10.5 months |